UROTHELIAL CANCER

This study offers continued treatment with avelumab for people with advanced cancers like lung, ovarian, or bladder cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug and monitor safety and survival. About 68 participants w…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) or adding nivolumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 1,300 participants who have not had prior treatment for inoperable or metastatic urothel…

This study tests two new drug combinations (tobemstomig alone or with tiragolumab) against an existing drug (atezolizumab) in 204 people with advanced bladder cancer who cannot receive platinum chemotherapy. The goal is to see if these combinations are safer and more effective. P…

This study tests a targeted pill (erdafitinib) against standard chemotherapy or immunotherapy for people with advanced bladder cancer that has specific FGFR gene changes. About 629 participants who have already tried other treatments will be randomly assigned to receive the new d…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This study tests a drug called erdafitinib in people with advanced bladder cancer that has certain changes in FGFR genes. The goal is to see if the drug can shrink tumors. About 239 participants will receive one of two dose schedules. The drug is taken as a pill and works by bloc…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This early-stage trial was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer that had not been treated before. The goal was to see if the combination was safe and could help control the cancer. Howe…

This study tested two immunotherapy drugs (durvalumab alone or combined with tremelimumab) against standard chemotherapy in over 1,100 people with stage IV bladder cancer that could not be removed by surgery. The goal was to see if these treatments helped people live longer. The …

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is give…

This study creates a registry of over 3,500 people, including those with and without urothelial cancer, to better understand the disease. Researchers will look at genetic markers in saliva and risk factors to find links to cancer risk and outcomes. The goal is to improve how we p…